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To the Editor: Since the identification of HIV-1 as the pri-
mary cause of AIDS, much effort has been made to develop 
therapies that potently inhibit virus replication. Unfortunately, 
HIV-1 uses an error-prone replication machinery that allows 
the virus to rapidly adapt to new conditions. As a conse-
quence,  early  single-drug  therapies  failed  because  of  the 
rapid appearance of drug-resistant virus variants. The simul-
taneous use of multiple drugs prevents viral escape because 
mutations are required in multiple drug targets. This combi-
natorial antiretroviral therapy significantly improved the pros-
pects of HIV-1 infected patients. However, multidrug-resistant 
viruses can emerge and drug toxicity is an issue, thus new 
antiviral therapies are needed.
Gene therapy based on RNA interference (RNAi) seems 
to be a promising new strategy to fight chronic HIV-1 infec-
tion. Arming cells with small interfering RNAs (siRNAs) trig-
gers degradation of the complementary HIV-1 RNA genome. 
A single siRNA can yield a potent antiviral effect, but the 
virus can escape by acquiring mutations in the siRNA-target 
sequence.  Combinatorial  RNAi  approaches  prevent  viral 
RNAi escape because it requires acquisition of mutations 
in all siRNA-target sites. However, in their recent article in 
Molecular Therapy  titled “HIV  Develops  Indirect  Cross-re-
sistance to Combinatorial RNAi Targeting Two Distinct and 
Spatially Distant Sites”1, Shah et al. suggest that HIV-1 can 
escape from combinatorial RNAi by the selection of muta-
tions in regions of the viral genome other than the actual 
RNAi  targets,  thus  seriously  challenging  the  potential  of 
combinatorial RNAi in the fight against HIV-1.
The authors generated T-cell lines that stably produced a 
single or two siRNAs (Ldr3 and TatB2) that were developed 
in  previous  studies.2,3  In  patients  undergoing  RNAi-based 
gene therapy, only a fraction of the cells would be modified. 
To mimic this situation, the authors mixed siRNA-producing 
cells with unmodified cells. In agreement with previous stud-
ies, the chosen siRNAs inhibited HIV-1 replication and the 
combinatorial  approach  was  most  effective.  Nevertheless, 
break-through virus replication was observed within 32 days 
of follow-up, which resulted in a high virus titer. The percent-
age of cultures in which the virus escaped from RNAi sup-
pression was ~25% for Ldr3 cells, ~65% for TatB2 cells, and 
~10% for Ldr3+TatB2 cells. The authors sequenced parts 
of the HIV-1 genome to identify sequence changes that are 
responsible for viral escape. Single point mutations were fre-
quently observed in the siRNA targets, but only in part of the 
virus population. This inspired the authors to look for alterna-
tive escape scenarios by sequencing other parts of the HIV-1 
genome. Mutations were detected in all regions, but only the 
U3  promoter  region  acquired  statistically  more  mutations 
in the Ldr3 and Ldr3+TabB2 cells than in unprotected and 
TatB2 cells.
The replication capacity was determined for 12 candidate 
escape viruses with U3 mutations but no changes in the siR-
NA-target sequence. Cells were infected and the viral burst 
size was calculated as the cumulative viral titer by integrating 
the 10-day replication curves. Based on differences observed 
in this burst size, 4 of the 12 virus variants were found to rep-
licate more efficiently than the wild-type virus in the siRNA-
expressing cells in which they had been selected, suggesting 
that these viruses had developed siRNA resistance. Two of 
the four resistant viruses showed an increased burst size in 
Ldr3 cells in which they had been selected and the unrelated 
TatB2 cells, which the authors interpret as cross-resistance. 
Finally, the authors show that two of the four “RNAi-resistant” 
virus variants can produce more viral transcripts than wild-
type virus upon infection of cells, suggesting that RNAi eva-
sion was due to transcriptional upregulation.
Summarizing, the authors suggest that HIV-1 can develop 
indirect resistance to RNAi therapy, including a combinatorial 
attack, by acquiring mutations in the unrelated U3 promoter 
region. We, however, believe that there are alternative pos-
sible explanations for these findings. In our view, the authors 
dismiss  the  direct  escape  route  too  easily  and  have  not 
demonstrated that the U3 mutations cause general siRNA 
escape.
Several studies have shown that HIV-1 and other viruses 
can escape from RNAi pressure by a single mutation in the 
siRNA-target sequence.4–9 The data presented in Table 1 of 
Shah et al. show that such mutations are present in two (out 
of three) Ldr3 and three (out of three) TatB2 cultures. Muta-
tions were also observed in eight (out of nine) combinato-
rial siRNA cultures, either in one or both siRNA targets. The 
authors dismiss the simple scenario that these target muta-
tions cause viral escape because they were not present in 
the complete virus population. However, this may relate to 
the use of mixed cell cultures. The escape viruses will never 
outcompete the wild-type virus that can replicate unhindered 
in the unmodified cells (Figure 1). This effect will be mag-
nified when the RNAi-resistant viruses exhibit a replication 
deficit. Such fitness losses are likely when well-conserved 
viral sequences are targeted, as is the case for the chosen 
siRNAs.10 Remarkably, the “no-fixation” argument that was 
used to dismiss direct target site mutations, was not used to 
scrutinize the indirect U3 region mutations. Supplementary 
Table S2 of Shah et al. shows that very few U3 mutations 
became fixed in the many cultures tested. Of these, the most 
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frequent change (T-1G, observed in three cultures) has been 
detected repeatedly in HIV-1 evolution studies in the absence 
of any RNAi pressure (see e.g., ref. 11,12).
Most importantly, the replication assays used do not con-
vincingly demonstrate an RNAi-resistance effect of the U3 
mutations. The viral burst size is a rather unusual and dan-
gerous measure for virus replication as improved virus rep-
lication can cause increased cell death that translates into 
a lower burst size. Only four of the 12 U3-mutated viruses 
showed  an  increased  burst  size  when  tested  on  siRNA-
expressing  cells.  Only  two  of  these  four  variants  showed 
cross-resistance, which would mean that the U3 mutations 
in the other two variants provide resistance against a spe-
cific siRNA. The other eight variants did not show any RNAi 
resistance, whereas these viruses carried similar mutations 
in the U3 region. In fact, the replication curves in the Supple-
mentary Figure S3 of Shah et al. show that the four “RNAi-
resistant” virus variants are similarly inhibited by the siRNAs 
as the wild-type virus, which demonstrates that they are not 
RNAi resistant.
Is there perhaps any evidence for a transcriptional impact 
of the U3 mutations on the HIV-1 long terminal repeat (LTR) 
promoter? To answer this question, Shah et al. infected cells 
with the virus variants and quantified the intracellular viral 
transcripts after 3 days. This is however not a proper assay to 
measure transcription, because the read out is dependent on 
several processes, including RNA genome packaging (deter-
mining the RNA content of the virus stock), virus infection, 
reverse transcription of the RNA genome, integration of the 
newly made viral DNA, transcription, RNA processing, and 
translation. Thus, the difference measured for U3-mutated 
viruses does not simply reflect different transcriptional activity 
of the U3 promoter, but can be due to a difference in another 
process. Again, this phenotype was not seen for all tested U3 
mutants, but only for two of the four selected variants. Only 
one of these two showed cross-resistance, whereas the pro-
posed mechanism would cause general RNAi resistance.
In toto, the role of the siRNA-target site mutations in RNAi 
escape was dismissed too easily and the RNAi-resistance 
effect of the newly identified U3 changes is questionable. In 
addition, the proposed escape by upregulation of viral tran-
scription was not properly tested. In numerous HIV-1 evolution 
studies, we observed that every escape culture had acquired 
a mutation in the target site.8 This was subsequently veri-
fied by recloning and retesting, demonstrating that a single 
target site mutation is required and sufficient for resistance, 
although some cultures acquire a second mutation over time 
to reach high-level resistance. One notable exception was 
described that represents a more indirect escape route. We 
infrequently observed the selection of a point mutation just 
outside the actual target sequence, which causes a rear-
rangement of the local RNA structure that restricts access of 
the RNA machinery.13,14
The Schaffer laboratory previously reported a similar indi-
rect compensatory mechanism by which HIV-1 evades anti-
viral RNAi action.15 Specifically, evidence was presented that 
HIV-1 selects up-mutations in the viral promoter to overcome 
RNAi pressure imposed by siRNAs against the TAR motif. 
Also then, the idea was that tuning of viral gene expression 
by promoter upregulation represents a general mechanism 
by which viruses escape from RNAi therapy. However, we 
have argued that the observed promoter changes do reflect 
a general improvement of the attenuated HIV-1 strain that 
was used in these evolution experiments and not a general 
RNAi escape route.16 In fact, exactly the same HIV-1 pro-
moter  modification—duplication  of  the  three  Sp1  binding 
sites to form six sites—was reported previously for this atten-
uated virus by spontaneous virus evolution in extended cul-
tures in the absence of any RNAi pressure.17 The absence of 
direct viral escape routes by mutation of the target sequence 
may relate to the mediocre potency of the anti-TAR siRNAs 
used in the Leonard study.15 These siRNAs gave only 20% 
knock-down in transient transfection assays with a reporter 
construct, which may relate to the stable hairpin structure of 
the viral TAR target.18
In the absence of more convincing evidence against the 
efficacy of a combinatorial RNAi attack, it seems imperative 
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Figure 1  hiV-1 escape from sirNA therapy in different culture 
systems. Virus evolution is usually studied in pure cultures of siRNA-express-
ing cells that are protected against HIV-1 infection (left panel). Variants will be 
generated at a low rate because the block in virus replication is not absolute. 
Only the siRNA-resistant variant (red circle) will be able to replicate and spread 
on these cells (passage through the red funnel). Shah et al. used mixed cell 
cultures of protected and unprotected cells to study HIV-1 evolution under siRNA 
pressure (right panel). The bulk of virus replication will occur in the unprotected 
cells (passage through gray funnel), leading to the rapid generation of a viral 
quasispecies by spontaneously acquired mutations. This quasispecies may also 
contain a siRNA-resistant variant that is able to replicate in the protected cells. 
The latter mutant could also be generated in the protected cells, but at a reduced 
rate due to siRNA-mediated suppression of virus replication. The outcome of 
these two evolution scenarios is strikingly different: the siRNA-resistant HIV-1 
variants dominate the culture in the left panel, but remain as minority variants in 
the right panel. siRNA, small interfering RNA. 
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impressed by the finding that a combinatorial RNAi approach 
with four siRNAs is able to permanently block virus evolution.3 
This concept is currently being tested in humanized mice as 
preclinical test system for a future ex vivo gene therapy.19 We 
realize that there may be many hurdles along this route, but 
viral escape by indirect routes does not seem to be a major 
issue.
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